We are live on ! Find out more
O

OrbiMed Portfolio holdings

AUM $5.4B
1-Year Est. Return 163.13%
This Fund
S&P 500
This Quarter Est. Return
+33.14%
1 Year Est. Return
+163.13%
3 Year Est. Return
+393.16%
5 Year Est. Return
+486.34%
10 Year Est. Return
+3,312.73%
AUM
$7.1B
AUM Growth
+$1.15B
Cap. Flow
-$108M
Cap. Flow %
-1.52%
Top 10 Hldgs %
31.14%
Holding
166
New
24
Increased
29
Reduced
28
Closed
31

Top Buys

Rank Stock Value
1
BNR
Burning Rock Biotech
BNR
+$130M
2
RPTX
Repare Therapeutics
RPTX
+$110M
3
ORIC icon
Oric Pharmaceuticals
ORIC
+$93.3M
4
BIIB icon
Biogen
BIIB
+$70.8M
5
TBPH icon
Theravance Biopharma
TBPH
+$60.2M

Top Sells

Rank Stock Value
1
ASND icon
Ascendis Pharma A/S
ASND
+$237M
2
PFE icon
Pfizer
PFE
+$98.3M
3
GILD icon
Gilead Sciences
GILD
+$98M
4
ALEC icon
Alector
ALEC
+$64.9M
5
HCA icon
HCA Healthcare
HCA
+$63.8M

Sector Composition

Rank Sector Weight
1 Healthcare 97.96%
2 Financials 1.61%
3 Miscellaneous 0.43%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
TRIL
101
DELISTED
Trillium Therapeutics Inc.
TRIL
$9.8M 0.14%
1,211,000
+410,000
+51% +$2.54M
HRTX icon
102
Heron Therapeutics
HRTX
$59.9M
$9.71M 0.14%
660,420
+123,000
+23% +$2.02M
EPIX
103
DELISTED
ESSA Pharma
EPIX
$9.13M 0.13%
1,471,853
– –
PGNY icon
104
Progyny
PGNY
$2.1B
$8.8M 0.12%
+341,004
New +$7.83M
IMVT icon
105
Immunovant
IMVT
$7.78B
$8.63M 0.12%
354,575
+175,075
+98% +$3.75M
ANAB icon
106
AnaptysBio
ANAB
$1.6B
$8.39M 0.12%
375,800
– –
XTNT icon
107
Xtant Medical Holdings
XTNT
$46M
$8.32M 0.12%
9,248,678
+41,666
+0.5% +$38.2K
TXG icon
108
10x Genomics
TXG
$9.13B
$8.28M 0.12%
92,700
– –
CLDX icon
109
Celldex Therapeutics
CLDX
$3.08B
$8.13M 0.11%
+625,000
New +$2.77M
RCKT icon
110
Rocket Pharmaceuticals
RCKT
$377M
$8M 0.11%
+382,400
New +$6.89M
AKUS
111
DELISTED
Akouos Inc
AKUS
$7.09M 0.1%
+315,000
New +$7.02M
WHWK
112
Whitehawk Therapeutics
WHWK
$234M
$6.49M 0.09%
346,263
– –
APTO
113
DELISTED
Aptose Biosciences, Inc.
APTO
$6M 0.08%
2,113
+649
+44% +$2.09M
RNAC icon
114
Cartesian Therapeutics
RNAC
$248M
$5.95M 0.08%
69,796
-16,666
-19% -$1.51M
IGMS
115
DELISTED
IGM Biosciences
IGMS
$5.89M 0.08%
80,760
– –
VRNA
116
DELISTED
Verona Pharma
VRNA
$5.85M 0.08%
1,250,396
– –
RNAM
117
DELISTED
Avidity Biosciences
RNAM
$5.65M 0.08%
+200,000
New +$5.77M
RCUS icon
118
Arcus Biosciences
RCUS
$3.06B
$5.45M 0.08%
+220,350
New +$5.95M
AGIO icon
119
CALL
Agios Pharmaceuticals
AGIO
$2.01B
$5.35M 0.08%
100,000
-150,000
-60% -$6.95M
HCAT icon
120
Health Catalyst
HCAT
$128M
$5.24M 0.07%
179,598
– –
CALT
121
DELISTED
Calliditas Therapeutics AB American Depositary Shares
CALT
$5.22M 0.07%
+225,000
New +$4.46M
ARNA
122
DELISTED
Arena Pharmaceuticals Inc
ARNA
$4.2M 0.06%
66,700
-66,700
-50% -$3.67M
SYBX
123
DELISTED
Synlogic
SYBX
$4.12M 0.06%
135,333
– –
PPBT
124
Purple Biotech
PPBT
$2.86M
$3.84M 0.05%
1,731
– –
NBRV
125
DELISTED
Nabriva Therapeutics plc Ordinary Shares Ireland
NBRV
$3.13M 0.04%
18,578
– –
3 4
5
6 7

Similar funds

MYIA
Mount Yale Investment Advisors Denver, Colorado $5.4B AUM 28.46% 1-Year Est. Return
SCM
Shelton Capital Management Denver, Colorado $5.39B AUM 56.42% 1-Year Est. Return
BJL
Brighton Jones LLC Seattle, Washington $5.38B AUM 27.31% 1-Year Est. Return
BG
Baupost Group Boston, Massachusetts $5.42B AUM 22.93% 1-Year Est. Return
SNT
SIG North Trading Bala Cynwyd, Pennsylvania $5.42B AUM 31.03% 1-Year Est. Return
NL
NEPC LLC Boston, Massachusetts $5.36B AUM 7.83% 1-Year Est. Return
RC
Resolution Capital Sydney, NSW, Australia $5.44B AUM 27.71% 1-Year Est. Return
AC
AlphaCore Capital La Jolla, California $5.44B AUM 26.35% 1-Year Est. Return

OrbiMed's Q2 2020 Portfolio in Review

As of Q2 2020, OrbiMed held 166 positions worth $7.1B, up 19% from $5.95B the previous quarter. Its ten largest holdings account for 31% of the portfolio.

OrbiMed's Q2 2020 filing shows 24 new, 29 increased, 28 reduced and 31 closed positions. Its largest new stake was Burning Rock Biotech: 474,607 shares worth $128M. The largest sale was Ascendis Pharma A/S, an estimated $237M.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, up from 97% a quarter earlier, followed by Financials and Miscellaneous.

  • OrbiMed's largest Q2 2020 buy was Burning Rock Biotech: 474,607 shares worth $128M.
  • OrbiMed added most to Biogen in Q2 2020, an estimated $70.8M increase.
  • OrbiMed's biggest Q2 2020 reduction was Ascendis Pharma A/S, cutting an estimated $237M.
  • OrbiMed fully exited Pfizer in Q2 2020, selling an estimated $98.3M.
  • OrbiMed's ten largest holdings make up 31% of its $7.1B portfolio in Q2 2020.
  • OrbiMed opened 24 new positions and closed 31 in Q2 2020.
  • OrbiMed's portfolio value rose 19% quarter-over-quarter to $7.1B.

Based on OrbiMed's 13F filing for Q2 2020, filed 14 Aug 2020.